Welcome to our dedicated page for Processa Pharmaceuticals news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals stock.
Processa Pharmaceuticals, Inc. (PCSA) generates a steady flow of news as a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies and advancing select non-oncology programs. News coverage for PCSA commonly centers on its lead asset NGC-Cap (PCS6422 plus capecitabine) in advanced or metastatic breast cancer, where the company reports on Phase 2 trial enrollment milestones, interim analyses, and emerging safety and pharmacokinetic data.
Investors following PCSA news can expect detailed updates on clinical trial progress, including randomized Phase 2 study design features, preliminary findings on cancer-killing metabolite exposure, and comparative safety versus standard capecitabine monotherapy. Releases have highlighted how NGC-Cap may increase exposure to active metabolites while reducing toxic catabolites such as FBAL, along with observations on side-effect profiles like hand-foot syndrome.
Beyond oncology, Processa news also covers its rare disease and gastrointestinal programs, such as PCS499 in focal segmental glomerulosclerosis (FSGS) and PCS12852 for gastroparesis and related gastrointestinal motility disorders. Announcements have included acceptance of abstracts for major meetings like ASN Kidney Week and the signing of a binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852, with associated milestone, royalty, and equity terms.
PCSA news items frequently address capital markets and corporate strategy, including public offerings, private placements, reverse stock split approvals and implementation, and Nasdaq listing compliance updates. The company has also disclosed its evaluation of corporate cryptocurrency treasury strategies as part of its financial planning. In addition, Processa regularly announces participation in high-profile industry events such as the BIO International Convention, the American Society of Clinical Oncology (ASCO) Annual Meeting, and the J.P. Morgan Healthcare Conference, where management meets with investors and potential partners.
By monitoring this news feed, readers can track how Processa’s NGC platform, pipeline decisions, partnership activities, and financing events evolve over time, all based on the company’s own press releases and regulatory disclosures.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) will hold a conference call on August 12, 2021, at 5:30 p.m. EST to discuss second quarter results and updates on its clinical pipeline. The company focuses on developing treatments for patients with high unmet medical needs, currently advancing three drugs: PCS499 for Ulcerative Necrobiosis, PCS3117 for metastatic pancreatic and non-small cell lung cancers, and PCS6422 for metastatic colorectal and breast cancers. An IND for PCS12852 targeting gastroparesis is expected in 3Q2021.
Processa Pharmaceuticals has initiated its Phase 1b clinical trial for PCS6422, targeting patients with advanced, refractory gastrointestinal cancer. The first patient has been dosed in this multicenter study, which aims to assess the safety and pharmacokinetics of PCS6422 in combination with capecitabine. Interim results are expected by the end of 2021, with further studies planned for 2022 to establish maximum tolerated doses and biomarkers. The trial represents a significant step in developing therapies for patients with unmet needs in cancer treatment.
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) will present at the "Zooming with LD Micro" virtual investor event on July 29, 2021, at 12:00 PM ET. Investors can register for the event on the company's website. Processa focuses on developing treatments for unmet medical needs and has a team experienced in over 30 FDA drug approvals. The company emphasizes improving patient survival and quality of life through its innovative products.
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) will present at the Access to Giving Virtual Conference on July 14, 2021, at 10:30 a.m. ET. The presentation will be led by CEO Dr. David Young. The conference targets a range of companies and facilitates one-on-one meetings with qualified investors, who will donate to participate. Processa focuses on developing treatments for unmet medical needs, supported by a team with extensive FDA approval experience. For registration, visit here.
Processa Pharmaceuticals (NASDAQ: PCSA) has entered into a licensing agreement with Ocuphire Pharma (NASDAQ: OCUP) for RX-3117, an oral anticancer agent with FDA Orphan Designation for pancreatic cancer. The agreement grants Processa an exclusive worldwide license (excluding China) to develop and commercialize RX-3117. A Phase 2b trial is set to begin in 2022 to evaluate biomarker correlations and clinical effectiveness in patients with pancreatic and non-small cell lung cancer. The program aims to improve treatment options for patients needing better survival rates.
Processa Pharmaceuticals (NASDAQ: PCSA) announced it will join the Russell Microcap Index after the annual reconstitution on June 28, 2021. This inclusion signifies a substantial milestone for the company, potentially enhancing its visibility among investors and providing access to a wider investment base. The Russell indexes are crucial as they benchmark approximately $10.6 trillion in assets, suggesting that Processa's membership could attract more institutional investors. The company focuses on developing therapies for unmet medical needs, emphasizing treatments for various serious conditions.
Processa Pharmaceuticals (NASDAQ: PCSA) announced its participation in the LD Micro Virtual Investor Conference, scheduled for June 9, 2021, at 1:30 p.m. ET, Track 4. Management will present details about the company's pipeline aimed at improving survival and quality of life for patients with unmet medical needs. Current programs include PCS6422 for cancer treatments, PCS499 for ulcerative necrobiosis lipoidica, and PCS12852 for gastrointestinal issues. A live audio webcast of the event will be available for attendees.
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced its participation in two upcoming investor conferences. They will attend the Craig-Hallum Virtual Institutional Investor Conference on June 2, focusing on one-on-one meetings. Additionally, they will present at the Jefferies Virtual Healthcare Conference on June 4, from 2:00 to 2:25 PM EST, where one-on-one meetings will also be available. The company is committed to developing products to enhance survival and quality of life for patients with unmet medical needs.
Processa Pharmaceuticals (NASDAQ: PCSA) has dosed its first patient in a Phase 2B trial for PCS499, targeting ulcerations in patients with Necrobiosis Lipoidica (NL), a rare skin disease affecting collagen. The trial aims to assess the efficacy of PCS499 compared to a placebo. Approximately 30% of NL patients experience open ulcers that impair quality of life. Sian Bigora, Chief Development Officer, expressed optimism about the trial's potential impact on treatment options for this underserved condition.
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced its participation in two investor conferences aimed at addressing unmet medical needs. The events include the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021 (on-demand presentations) and The Benchmark Company Healthcare House Call Virtual Conference on May 26, 2021 (one-on-one meetings). Processa focuses on developing treatments for conditions such as metastatic colorectal cancer, breast cancer, and GI motility disorders. The company aims to enhance patient survival and quality of life through existing clinical evidence.